Resveratrol Butyrate Ester Supplementation Blunts the Development of Offspring Hypertension in a Maternal Di-2-ethylhexyl Phthalate Exposure Rat Model

Resveratrol (REV) is a plant polyphenol with a plethora of beneficial properties. We previously enhanced the efficacy of REV via esterification of REV with butyrate to form resveratrol butyrate ester (RBE). Compared with REV, RBE exhibits higher bioavailability and better antioxidant effects. Hypertension can originate in early life because of maternal toxic chemical exposure. This study aims to examine the effectiveness of RBE in the protection of offspring hypertension induced by maternal di-2-ethylhexylphthalate (DEHP) exposure and to explore the underlying mechanisms. DEHP (10 mg/kg/day) was used as oral gavage to pregnant rats during gestation and lactation. The control group received the vehicle. Three groups of DEHP-exposed dams received REV (6.67 mg/kg/day), or low-dose (3.33 mg/kg/day) or high-dose (6.67 mg/kg/day) RBE in drinking water during gestation and lactation. Perinatal DEHP exposure resulted in hypertension and bodyweight gain in adult male offspring, which was prevented by high-dose RBE. REV supplementation attenuated DEHP exposure-induced increases in blood pressure but not bodyweight. High-dose RBE decreased renal oxidative damage, increased plasma butyrate concentrations, and altered short chain fatty acid receptor (SCFA) expression. Low-dose RBE treatment reduced downstream mediators of the acryl hydrocarbon receptor (AHR) signaling pathway. Moreover, DEHP exposure, REV and RBE treatment differentially shaped the offspring’s gut microbiota. In particular, high-dose RBE increased the abundance of the genus Duncaniella. The beneficial effects of RBE treatment were related to reducing oxidative damage, increasing plasma butyrate concentrations, downregulating SCFA receptor expression, antagonizing AHR signaling, and altering the gut microbiota. This study provides the first evidence of RBE as a novel plant polyphenol bioproduct targeting the oxidative stress and gut microbiota to protect against maternal DEHP exposure-primed offspring hypertension.

[1]  G. Chang-Chien,et al.  Sodium Butyrate Modulates Blood Pressure and Gut Microbiota in Maternal Tryptophan-Free Diet-induced Hypertension Rat Offspring. , 2022, The Journal of nutritional biochemistry.

[2]  S. Clare,et al.  Identification of gut microbial species linked with disease variability in a widely used mouse model of colitis , 2022, Nature Microbiology.

[3]  Chi-I Chang,et al.  Resveratrol Butyrate Ester Protects Adenine-Treated Rats against Hypertension and Kidney Disease by Regulating the Gut–Kidney Axis , 2021, Antioxidants.

[4]  Y. Tain,et al.  Adverse Impact of Environmental Chemicals on Developmental Origins of Kidney Disease and Hypertension , 2021, Frontiers in Endocrinology.

[5]  Chi-I Chang,et al.  Perinatal Resveratrol Therapy to Dioxin-Exposed Dams Prevents the Programming of Hypertension in Adult Rat Offspring , 2021, Antioxidants.

[6]  Y. Tain,et al.  Preventive Aspects of Early Resveratrol Supplementation in Cardiovascular and Kidney Disease of Developmental Origins , 2021, International journal of molecular sciences.

[7]  Chien-Te Lee,et al.  Maternal Resveratrol Therapy Protected Adult Rat Offspring against Hypertension Programmed by Combined Exposures to Asymmetric Dimethylarginine and Trimethylamine-N-oxide: Resveratrol and gut microbiota in programmed hypertension. , 2021, The Journal of nutritional biochemistry.

[8]  Y. Tain,et al.  Synthesis of Short-Chain-Fatty-Acid Resveratrol Esters and Their Antioxidant Properties , 2021, Antioxidants.

[9]  J. Chan,et al.  Altered Gut Microbiota and Its Metabolites in Hypertension of Developmental Origins: Exploring Differences between Fructose and Antibiotics Exposure , 2021, International journal of molecular sciences.

[10]  G. Chang-Chien,et al.  Perinatal Resveratrol Therapy Prevents Hypertension Programmed by Maternal Chronic Kidney Disease in Adult Male Offspring: Implications of the Gut Microbiome and Their Metabolites , 2020, Biomedicines.

[11]  Y. Tain,et al.  Synthesis and Characterization of Novel Resveratrol Butyrate Esters That Have the Ability to Prevent Fat Accumulation in a Liver Cell Culture Model , 2020, Molecules.

[12]  Hailing Shao,et al.  The Endocrine Disruption of Prenatal Phthalate Exposure in Mother and Offspring , 2020, Frontiers in Public Health.

[13]  M. Reale,et al.  Critical Review on the Presence of Phthalates in Food and Evidence of Their Biological Impact , 2020, International journal of environmental research and public health.

[14]  E. Cairrão,et al.  Phthalates Implications in the Cardiovascular System , 2020, Journal of cardiovascular development and disease.

[15]  Yi Zhao,et al.  Aryl Hydrocarbon Receptor as a target for lycopene preventing DEHP-induced spermatogenic disorders. , 2020, Journal of agricultural and food chemistry.

[16]  Y. Tain,et al.  Maternal Exposure to Bisphenol A Combined with High-Fat Diet-Induced Programmed Hypertension in Adult Male Rat Offspring: Effects of Resveratrol , 2019, International journal of molecular sciences.

[17]  Francesco Asnicar,et al.  Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2 , 2019, Nature Biotechnology.

[18]  Subash C. Gupta,et al.  Health benefits of resveratrol: Evidence from clinical studies , 2019, Medicinal research reviews.

[19]  R. S. Bhaskaran,et al.  Developmental exposure to DEHP alters hepatic glucose uptake and transcriptional regulation of GLUT2 in rat male offspring. , 2019, Toxicology.

[20]  J. Mercader,et al.  Resveratrol, Metabolic Syndrome, and Gut Microbiota , 2018, Nutrients.

[21]  Y. Tain,et al.  Maternal Resveratrol Therapy Protects Male Rat Offspring against Programmed Hypertension Induced by TCDD and Dexamethasone Exposures: Is It Relevant to Aryl Hydrocarbon Receptor? , 2018, International journal of molecular sciences.

[22]  F. Altieri,et al.  Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans , 2017, Oxidative medicine and cellular longevity.

[23]  U. Förstermann,et al.  Antioxidant effects of resveratrol in the cardiovascular system , 2017, British journal of pharmacology.

[24]  J. Pluznick Microbial Short-Chain Fatty Acids and Blood Pressure Regulation , 2017, Current Hypertension Reports.

[25]  U. Das,et al.  Beneficial action of resveratrol: How and why? , 2016, Nutrition.

[26]  S. Shyue,et al.  Maternal exposure to di-(2-ethylhexyl) phthalate exposure deregulates blood pressure, adiposity, cholesterol metabolism and social interaction in mouse offspring , 2016, Archives of Toxicology.

[27]  J. Dyck,et al.  Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of long-term control of arterial blood pressure by resveratrol , 2014, Front. Physiol..

[28]  X. Chen,et al.  Maternal exposure to di-(2-ethylhexyl)phthalate alters kidney development through the renin-angiotensin system in offspring. , 2012, Toxicology letters.

[29]  Peter Gluckman,et al.  Developmental origins of noncommunicable disease: population and public health implications. , 2011, The American journal of clinical nutrition.

[30]  M. Usami,et al.  Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induced liver injury in rats. , 2011, Clinical nutrition.

[31]  T. Walle Bioavailability of resveratrol , 2011, Annals of the New York Academy of Sciences.

[32]  K. Sonoyama Metabolic syndrome and gut microbiota. , 2010 .

[33]  L. Lavis Ester bonds in prodrugs. , 2008, ACS chemical biology.

[34]  A. Nynca,et al.  Effects of Acute and Chronic Exposure to the Aryl Hydrocarbon Receptor Agonist 2,3,7,8-Tetrachlorodibenzo-p-Dioxin on the Transition to Reproductive Senescence in Female Sprague-Dawley Rats1 , 2006, Biology of reproduction.

[35]  J F Reckelhoff,et al.  Gender Differences in the Regulation of Blood Pressure , 2001, Hypertension.

[36]  Ian L. Rogers,et al.  Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. , 1999, Molecular pharmacology.